Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming H.C. Wainwright Global Investment Conference.
Management will deliver their presentation on Monday, September 8, 2025, at 12:00 PM ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days after the event. Investors can arrange meetings with management through their H.C. Wainwright representatives.
Vaxart (OTCQX: VXRT), azienda biotecnologica in fase clinica specializzata in vaccini ricombinanti orali in formato pillola, ha annunciato la partecipazione al prossimo H.C. Wainwright Global Investment Conference.
La direzione terrà la presentazione lunedì 8 settembre 2025 alle 12:00 ET. La presentazione sarà trasmessa in webcast sul sito degli investitori della società e sarà disponibile in replica per 30 giorni dopo l'evento. Gli investitori possono organizzare incontri con la direzione attraverso i loro rappresentanti H.C. Wainwright.
Vaxart (OTCQX: VXRT), una compañía biotecnológica en fase clínica especializada en vacunas orales recombinantes en formato píldora, ha anunciado su participación en la próxima H.C. Wainwright Global Investment Conference.
La dirección ofrecerá su presentación el lunes 8 de septiembre de 2025 a las 12:00 PM ET. La presentación estará disponible por webcast en la web de relaciones con inversores de la compañía y habrá una retransmisión accesible durante 30 días tras el evento. Los inversores pueden concertar reuniones con la dirección a través de sus representantes de H.C. Wainwright.
Vaxart (OTCQX: VXRT)는 경구형 재조합 필 팩터 백신을 전문으로 하는 임상 단계의 생명공학 회사로, 다가오는 H.C. Wainwright Global Investment Conference에 참가한다고 발표했습니다.
경영진은 2025년 9월 8일 월요일 오후 12:00(동부시간)에 발표를 진행합니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 행사 종료 후 30일간 재생을 제공할 예정입니다. 투자자들은 H.C. Wainwright 담당자를 통해 경영진과의 미팅을 신청할 수 있습니다.
Vaxart (OTCQX: VXRT), une société biotechnologique en phase clinique spécialisée dans les vaccins recombinants oraux sous forme de comprimé, a annoncé sa participation à la prochaine H.C. Wainwright Global Investment Conference.
La direction présentera le lundi 8 septembre 2025 à 12h00 ET. La présentation sera accessible en webcast sur le site relations investisseurs de la société, avec une rediffusion disponible pendant 30 jours après l'événement. Les investisseurs peuvent organiser des réunions avec la direction via leurs représentants H.C. Wainwright.
Vaxart (OTCQX: VXRT), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf orale rekombinante Tablettenimpfstoffe spezialisiert hat, hat seine Teilnahme an der kommenden H.C. Wainwright Global Investment Conference angekündigt.
Das Management wird seine Präsentation am Montag, den 8. September 2025, um 12:00 Uhr ET halten. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein; eine Wiederholung steht 30 Tage nach der Veranstaltung zur Verfügung. Investoren können über ihre H.C. Wainwright-Ansprechpartner Meetings mit dem Management vereinbaren.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025.
Presentation Details:
Date and Time: Monday, September 8 at 12:00 PM ET
Webcast: Click Here
A live webcast will be available on the Company’s investor relations website at https://investors.vaxart.com, and a replay of the presentation will be available for 30 days following the conclusion of the event.
Investors interested in meeting with management during the conference may reach out to their H.C. Wainwright representative.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
| Vaxart Media and Investor Relations: |
| Matt Steinberg |
| FINN Partners |
| IR@vaxart.com |
| (646) 871-8481 |
This press release was published by a CLEAR® Verified individual.
FAQ
When is Vaxart (VXRT) presenting at the H.C. Wainwright Conference 2025?
How can investors access Vaxart's (VXRT) H.C. Wainwright presentation?
What does Vaxart (VXRT) specialize in?
How can investors meet with Vaxart management during the conference?
